Patients with concurrent malignancies pose significant diagnostic and therapeutic challenges. We report a rare and fatal case of synchronous ovarian mixed germ cell tumor and mast cell leukemia (MCL) ...

A significantly greater percentage of patients treated with mitapivat achieved hemoglobin response compared with those who received placebo. Topline results were announced from a phase 3 trial ...

For years, AI in drug discovery has been held back by a deceptively simple problem: the data isn’t good enough. Mountains of sequencing, pooled perturbation studies, and those mixed-cell experiments ...

Nov 19 (Reuters) - Agios Pharmaceuticals (AGIO.O), opens new tab said on Wednesday its sickle cell disease drug met one of its two main goals in a late-stage study of patients aged 16 and older but ...

For weeks, biotech investors have been bracing for the results of a large, late-stage trial of Agios Pharmaceuticals Pyrukynd pill in patients with sickle cell disease.

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its commercial outlook and the company’s reinvention. Uptake for the genetic ...

“Our goal is that by the end of this call, you’ll share our conviction in the totality of the data.” So said Agios Pharmaceuticals Inc. CEO Brian Goff as the company reported top-line data from its 52 ...